Keunchil Park

Research interests

Publications

• Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

  Journal of Clinical Oncology · 2021 · 10.1200/jco.21.00662

• Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

  British Journal of Cancer · 2020 · https://doi.org/10.1038/s41416-020-0802-1

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005653

• KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1917239

• Comprehensive molecular characterization of mitochondrial genomes in human cancers

  Nature Genetics · 2020 · https://doi.org/10.1038/s41588-019-0557-x

• Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-020-16164-1

• Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1910231

• Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30634-5

• Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30634-5

• DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

  Nature Communications · 2019 · 10.1038/s41467-019-12159-9

• Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30673-9

• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30144-x

• Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.71.9096

• Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

  The Lancet · 2016 · 10.1016/s0140-6736(16)00587-0

• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

  The Lancet · 2016 · 10.1016/s0140-6736(16)32517-x

• Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30033-x

• Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00021-2

• Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

  The Lancet · 2014 · 10.1016/s0140-6736(14)60845-x

• First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.36.8456

• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70087-6

• EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70318-7

• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

  The Lancet · 2009 · 10.1016/s0140-6736(09)60569-9

• Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.15.0375

• Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.04.1384

• A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability.

  PubMed · 1995

Current projects

No projects listed.